METAvivor funds research that specifically addresses the mechanistic understanding, diagnosis, and/or treatment of metastatic breast cancer. All individuals with a clinical doctoral degree or with a doctoral degree who are actively engaged in areas of metastatic breast cancer research and treatment are eligible to apply.
IMPORTANT Research Grant Change: Due to the Covid-19 (novel coronavirus) and many issues surrounding the quarantine of certain institutions, METAvivor is extending the deadline of both grants by one week. The new deadline for the Early Career Investigator LOI will be March 24, 2020 and the Translational Research LOI will be March 25, 2020.
The 2020 grant cycle is now open at https://metavivor.infoready4.com/. This year METAvivor is offering two awards focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients:
METAvivor Research Award (MRA) is a 2-year, $250,000 grant for established investigators.
METAvivor Early Career Investigator Award (ECIA) is a 1-year, $100,000 award available to early career applicants (investigators within 6 years of starting their first non-tenured position or within 10 years of receiving their professional degree).
Full award information, application details, and eligibility requirements can be found in the RFPs posted in the grant application portal at https://metavivor.infoready4.com/.
Thank you for your interest and participation.